Axon Enterprise, Inc. (NASDAQ:AXON) CAO Jennifer H. Mak Sells 75 Shares

Axon Enterprise, Inc. (NASDAQ:AXON - Get Free Report) CAO Jennifer H. Mak sold 75 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $771.81, for a total value of $57,885.75. Following the sale, the chief accounting officer now owns 15,240 shares of the company's stock, valued at $11,762,384.40. This trade represents a 0.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Axon Enterprise Stock Performance

NASDAQ:AXON traded down $0.02 on Monday, reaching $780.61. 470,489 shares of the company's stock were exchanged, compared to its average volume of 717,558. The firm has a market cap of $60.77 billion, a price-to-earnings ratio of 201.71, a P/E/G ratio of 5.17 and a beta of 1.29. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The stock has a fifty day simple moving average of $669.47 and a 200-day simple moving average of $621.44. Axon Enterprise, Inc. has a 52 week low of $279.02 and a 52 week high of $806.64.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The company had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same period last year, the firm earned $1.15 EPS. Axon Enterprise's revenue for the quarter was up 31.3% on a year-over-year basis. As a group, sell-side analysts predict that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

AXON has been the subject of several recent analyst reports. Barclays upped their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Northcoast Research downgraded shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 19th. Craig Hallum lowered shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. The Goldman Sachs Group boosted their target price on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Finally, Needham & Company LLC increased their price target on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, Axon Enterprise presently has a consensus rating of "Moderate Buy" and a consensus price target of $699.55.

Hedge Funds Weigh In On Axon Enterprise

Hedge funds have recently made changes to their positions in the stock. Anderson Financial Strategies LLC purchased a new stake in Axon Enterprise during the 1st quarter worth about $526,000. Strs Ohio purchased a new position in Axon Enterprise during the 1st quarter valued at about $45,265,000. Wealth Management Associates Inc. increased its position in shares of Axon Enterprise by 2.5% during the first quarter. Wealth Management Associates Inc. now owns 5,022 shares of the biotechnology company's stock valued at $2,641,000 after buying an additional 122 shares during the period. Geneos Wealth Management Inc. lifted its holdings in shares of Axon Enterprise by 11.8% in the first quarter. Geneos Wealth Management Inc. now owns 2,065 shares of the biotechnology company's stock worth $1,086,000 after buying an additional 218 shares in the last quarter. Finally, IFM Investors Pty Ltd boosted its position in shares of Axon Enterprise by 1.3% in the first quarter. IFM Investors Pty Ltd now owns 14,501 shares of the biotechnology company's stock valued at $7,627,000 after acquiring an additional 185 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.